MedPath

Fruquintinib

Generic Name
Fruquintinib
Brand Names
Fruzaqla
Drug Type
Small Molecule
Chemical Formula
C21H19N3O5
CAS Number
1194506-26-7
Unique Ingredient Identifier
49DXG3M5ZW
Background

Fruquintinib is under investigation for the treatment of NSCLC. Fruquintinib has been investigated for the treatment of ColoRectal Cancer.

Indication

本品单药适用于既往接受过氟尿嘧啶类、奥沙利铂和伊立替康为基础的化疗,以及既往接受过或不适合接受抗血管内皮生长因子(VEGF)治疗、抗表皮生长因子受体(EGFR)治疗(RAS野生型)的转移性结直肠癌(mCRC)患者。

Associated Conditions
-
Associated Therapies
-
finance.yahoo.com
·

CytomX Therapeutics Announces 2025 Strategic Pipeline Priorities and Provides Corporate Update

CX-2051 , targeting EpCAM for solid tumors, shows promise in Phase 1 for advanced CRC, with initial data expected in 2025. CX-904 , targeting EGFRxCD3, is advancing in Phase 1, with higher dose levels planned for 2025. CX-801 , a PROBODY® Interferon-alpha 2b, is in Phase 1 for metastatic melanoma, with data expected in late 2025.
menafn.com
·

Colorectal Cancer Market Report 2034: Epidemiology Data, Therapies, Latest FDA, EMA, PDMA Approvals

The Colorectal Cancer market is projected to grow significantly by 2034, driven by increasing prevalence and advancements in treatment. Key companies include Mirati Therapeutics , AstraZeneca , and Takeda , with therapies like FRUZAQLA and ENHERTU gaining FDA approval. The US leads in cases, with a focus on metastatic and MSS mutation types. Regular screenings and research are crucial for managing this major public health challenge.
tradingview.com
·

HUTCHMED to Receive Milestone Payment from Takeda following First European

HUTCHMED to receive US$10M milestone payment from Takeda following European approval and Spain's first national reimbursement for FRUZAQLA ® ( fruquintinib ), a novel oral targeted therapy for metastatic colorectal cancer.
msn.com
·

Hutchmed to receive milestone payment following Takeda launch of Fruzaqla

The article does not contain any readable content for summarization.
research-tree.com
·

FRUZAQLA® Launched in Japan by Takeda

HUTCHMED announces Takeda 's launch of FRUZAQLA ® ( fruquintinib ) in Japan, following approval by the Japanese Ministry of Health, Labour and Welfare in September 2024. This milestone triggers a payment to HUTCHMED and marks the first novel oral targeted therapy for metastatic colorectal cancer in Japan in over a decade.
investing.com
·

Earnings call: Takeda reports robust H1 growth, revises full-year guidance

Takeda Pharmaceutical reports 5% revenue growth in H1 FY24, driven by Growth & Launch portfolio, despite VYVANSE sales decline. The company raises full-year guidance, with core operating profit margin at 30.2%, and focuses on late-stage pipeline investments. Key highlights include ENTYVIO 's double-digit growth and Phase 3 trials for TAK-861 and mezagitamab .
quantisnow.com
·

Takeda Announces Strong First Half FY2024 Results and Raises Full Year Outlook

Takeda announced FY2024 H1 results with +13.4% revenue growth at AER and +5.0% at CER, driven by Growth & Launch Products (+18.7% at CER). Core Operating Profit increased +12.9% at CER, with a margin of 30.2%. ENTYVIO ® revenue grew double-digits at CER, and geographical expansions included ADZYNMA ® in EU and FRUZAQLA ® in Japan. A Phase 3 trial for TAK-861 in narcolepsy type 1 started, and an R&D Day is scheduled for December 12 (EST) / 13 (JST). The company upgraded FY2024 forecasts due to stronger-than-expected H1 performance and revised FX assumptions.

Global cancer cases surge while biotech firms accelerate treatment innovations

Global cancer cases surge, with a 79% rise in new cases among patients under 50. The highest death tolls are linked to breast, windpipe, lung, bowel, and stomach cancers. Cancer rates are projected to increase by 77% by 2050. In response, biotech firms like Oncolytics, AbbVie , BeiGene , HUTCHMED , and Enliven Therapeutics are accelerating treatment innovations, with the FDA approving 16 new oncology treatments in 2024. Oncolytics plans to submit a clinical trial for breast cancer treatment to the FDA in early 2025.
medcitynews.com
·

J&J Backs Down From 340B Rebates, But Maintains They're 'Legally Permissible' Per Statute

Johnson & Johnson proposed changes to the 340B drug discount program, but backed down after HRSA deemed them inconsistent with the statute. The 340B program, established in 1992, aims to help underserved communities by allowing eligible hospitals and clinics to purchase outpatient prescription medications at discounts. Recent regulatory developments include FDA approvals for Exact Sciences' Cologuard Plus , Partners Fresenius Kabi and Formycon's Otulfi , Eli Lilly's Retevmo , Sanofi and Regeneron's Dupixent , Bristol Myers Squibb's Cobenfy , and others. Additionally, Pfizer withdrew Oxbryta from the market due to safety concerns.
© Copyright 2025. All Rights Reserved by MedPath